knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 05:39:48 - browse：39

President of Bayer U.S. Sebastian Guth speaks with STAT reporters at STAT's Boston headquarters, March 13, 2024 — Bayer's U.S. president, Sebastian Guth, emphasized at an interview at the STAT offices in Boston that the pharma company is no longer just focused on small molecules. Alissa Ambrose/STAT

German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and pricing pressures that have led many in the drug industry to bemoan the potential end of the American biotech innovation boom.

Bayer’s C-suite has been on a soul-searching mission for the last year, spurred by new leadership and the realization that the company is, as new CEO Bill Anderson said earlier this month, “badly broken.”

The biggest fissure is the debt and litigation costs stemming from Bayers’s 2018 acquisition of agriculture firm Monsanto, but the aspirin-maker’s pharmaceutical portfolio is also facing strain. Some of Bayer’s top products, including the anticoagulant drug Xarelto and the eye medication Eylea, are under patent pressure. Xarelto is also one of the first drugs to be subject to Medicare price negotiations under the Inflation Reduction Act, though Johnson & Johnson owns U.S. rights to the drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

entertainment

WSS

Researchers test human milk's ability to repair gut microbiome

'A game

FDA panel to weigh safety of artificial wombs for preterm births

People with mental disorders often marry others with same

Florida Supreme Court upholds state's abortion ban

People with mental disorders often marry others with same

Wikipedia

knowledge

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

Free Covid tests will again be offered to all U.S. households

Duchenne breakthrough therapy leaves behind pioneering families

Multiple sclerosis has subtypes with different best treatments: study

23andMe had bad news about my health. I wish a person had delivered it

David Liu startup to focus on CRISPR delivery

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Oral obesity drug from Viking Therapeutics hits key early target

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

explore

Young boy dies in trial for Pfizer Duchenne gene therapy

The unintended consequences of overturning Roe v. Wade

What happened to the House vote on health price transparency?

Trial using CRISPR to edit HIV out of cells disappoints

Why the drug industry's warnings on the IRA's impact fall short

Medicare Advantage 2025 payments will dip, Biden administration says

entertainment

entertainment

hotspot

hotspot